TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Reduction in FIQ-R
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Hamilton Depression Rating Scale (HAM-D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hamilton Rating Scale for Anxiety (HAM-A)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Global Impression Scale CGI-BP
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Affective Morbidity Index
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Serum folate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Red blood cell (RBC) folate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum folic acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Gene-specific DNA methylation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Burnout Relief
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Total Mood
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change of IL-10 in pg/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: number of passes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with Moderate COVID-19
Endpoint domain: Mortality/survival
Primary endpoint: Rate of Positive COVID-19 nucleic acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Rate of Negative COVID-19 nucleic acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Total Body Weight Loss (TBWL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percent of Total Body Weight Loss (TBWL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of overall procedure or device related Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients exhibiting fibrinolysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric Mean Fold Rise (GMFR) in VZV Antibody Responses (gpELISA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Fold Rise (GMFR) in VZV Antibody Responses (ELISPOT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants Who Experience at Least 1 Serious Adverse Event (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Penn Alcohol Craving Scale Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Adverse Event Frequency
Endpoint domain: Adverse events/effects
Primary endpoint: Total rTMS Sessions Completed
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Maximum dose tolerated of nimodipine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: arterial partial pressures of oxygen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: BOLD signal change during visual cocaine vs. neutral cues
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of urines cocaine-positive or missing during outpatient phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of acute non variceal gastrointestinal tract bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: full-field flicker electroretinogram (ffERG) implicit time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: full-field flicker electroretinogram (ffERG) amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: glycosylated hemoglobin (HbA1c) percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time needed for the capsule to dissolve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Product distribution at 20 minute intervals within the first 90 minutes after insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Systemic levels of miconozole nitrate 90 minutes and 24 hours after insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of miconozole nitrate in the vagina 90 minutes and 24 hours after insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time needed to master motor control of the muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BOLD Responses in the vmPFC-VS circuit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Body weight after 52 weeks of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Participants Classified as an Overall Success
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Variation of Glutamine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in Daily Subject-reported AM and PM Reflective TNSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency and function of immune cell subsets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Flare to baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Flare at day 14
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in renal glomerular filtration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Aerobic bacterial colonization in oropharyngeal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Clinical Parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Carriage rate of Streptococcus pneumoniae
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: cure rate of BV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trough FEV1 (L) at 28 Weeks on Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Trough FEV1 (L) at 12 Weeks on Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Alveolar arterial O2 difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of patients achieving a decrease in corticosteroid treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean vertical ridge resorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Gingival Recession
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Papilla Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of bleeding on probing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Seroprotection or Booster Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Intraabdominal abscess
Endpoint domain: Adverse events/effects
Primary endpoint: serum C-reactive protein (CRP) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: prophylaxis effect on heart function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Undetectable plasma HCV RNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with hemoglobin less than 10 g/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Patency rate of vascular access
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Ventricular volumes and left ventricular remodeling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Insulin mediated glucose disposal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Antibody Concentration Against Protein D
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum drug concentration of tigecycline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Opioid-related symptom distress scale (SDS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: RECIST Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change from baseline in HIV RNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of LEO 22811
Endpoint domain: Adverse events/effects
Primary endpoint: Change on the Child Adolescent Trauma Screen (CATS) - Child Version
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change on the Pittsburgh Sleep Quality Index - Modified (PSQI) - Child Version
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change on the Nightmare Distress Questionnaire (NDQ)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Clinician Burnout
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: hs-TnT (High sensitivity troponin T) - 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: hs-TnT (High sensitivity troponin T) - 48 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: CK-MB (Creatine kinase- MB isoenzyme) - 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: CK-MB (Creatine kinase- MB isoenzyme) - 48 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Abnormal left ventricular geometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Dilated left atrium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety assessed through adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: AUC0-48 of levocetirizine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of levocetirizine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Treatment-emergent AEs or Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Relative Percent Change in Serum C-terminal Telopeptide of Type 1 Collagen Concentration (sCTX)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Health-related quality of life (15-D)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Costs of social and health care services
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in Shemesh 100 nouns test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: mutations in genes coding for complement activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Any atrial arrhythmia >30s documented on ECGs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Consciousness status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage change in triglycerides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Overall adherence score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: EEG amplitude changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: EEG frequency changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: ECoG amplitude changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: ECoG frequency changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Sputum Markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Diagnostic yield of TB culture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: mass balance recovery of total radioactivity in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mass balance recovery of total radioactivity in faeces
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Visual analog scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: State-Trait Anxiety Inventory (STAI-I, STAI-II)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Visual Comparison Sleep Scale
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Behavioral phenomena requiring intervention
Endpoint domain: Adverse events/effects
Primary endpoint: Red Blood Cell (RBC) 24-Hour Recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Composite Score of Change in NYHA Class
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Subjects Who Achieved ≥ 2-grade Improvement in IGA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone Age Assessment using Ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone Age Assessment by imaging method using X-Ray
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose of pramipexole
Endpoint domain: Adverse events/effects
Primary endpoint: molar urine recovery of niacin metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Cardiac Event 5-year Risk Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence and severity of treatment-emergent adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of diastolic dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of patients with complete resolution of heartburn and regurgitation symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Participants With Very Good Partial Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference between pre-induction temperature and intraoperative temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NPi®-200 pupillometer measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: NeurOptics PLR-3000 pupillometer measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Post-Concussion Symptom Inventory (PCSI) & Post-Concussion Symptom Scale (PCSS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT®)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Balance Error Scoring System (BESS) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Total Score on PTSD Checklist for DSM-5 (PCL-5)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Total Score on Inventory of Depressive Symptomatology, Self-Report (IDS-SR) Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Median Concentration of Aspartate Aminotransferase (AST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SIBSQ
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Percentage of nutritional changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Sensibility and specificity of PET (18F-FDG) for cGVH diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Flow Mediated Dilatation (FMD) of the Brachial Artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Patient Health Questionnaire-9 (PHQ-9)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Generalized Anxiety Disorder Screener-7 (GAD-7)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in The Warwick-Edinburgh Mental Wellbeing Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Portion of patients weaned off opioids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pre-bronchodilator FEV1 Rate of Decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Post-bronchodilator FEV1 Rate of Decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Safety and tolerability of E6007 as a measure of Adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: tmax (Time to achieve maximum concentration)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC (0-t) (Area Under the Curve from Time Zero to Last Quantifiable Concentration)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC (0-inf) (AUC extrapolated to infinity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Connectivity measures (apparent coefficient of diffusion, fractional anisotropy, radial and axial diffusivity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Metabolite concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary excretion of modified nucleosides
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve (AUC) concentrations of oxycodone hydrochloride injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in PANSS Marder Negative Factors Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tear Film Breakup Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Days of Substance Use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary Phosphorus Excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Normal Intracranial Pressure Values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of patients who are non-failures
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in visual analogue scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bronchodilator dose-effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Death or NEC (≧stage 2)
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of Subjects Achieving Pleurodesis Without Recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pancreatic perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Outflow adequacy of liver graft
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficiency of lymphaticovenous anastomosis (LVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change in Social Prediction abilities in the Action Prediction task
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Social Prediction abilities in the Virtual Reality scenario
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in peripheral O2 saturation (SpO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ability to up-size with tapered applicator
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agreement between CMR-derived FFR and FFR from angiography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of patients with cardiac events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ventilation efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Velocity of tooth movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interdialytic weight gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total number of new clinically visible AKs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Occurrence of reported hepatitis related outcomes
Endpoint domain: Adverse events/effects
Primary endpoint: post-operative redness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: grading of anterior chamber cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes